ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
120.832,31
0,68%
S&P 500
5.975,38
0,00%
US Dollar vs BRL
6,0777
-0,64%
Bitcoin
100.642,63
-1,61%
Brent Oil
76,745
0,83%
As Melhores Corretoras Online
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Ionis Pharmaceuticals Inc (IONS)

  7. Ionis Pharmaceuticals Inc (IONS) Notícias

IONS

Ionis Pharmaceuticals (IONS)

Ionis Pharmaceuticals Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:IONS
DataHoraFonteTítuloCódigoCompanhia
06/01/202519:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
20/12/202416:28Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IONSIonis Pharmaceuticals Inc
19/12/202420:28PR Newswire (US)TRYNGOLZA™ (olezarsen) approved in U.S. as first-ever treatment for adults living with familial chylomicronemia syndrome as an adjunct to dietNASDAQ:IONSIonis Pharmaceuticals Inc
14/11/202422:34Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:IONSIonis Pharmaceuticals Inc
13/11/202410:55Edgar (US Regulatory)Form 144/A - Report of proposed sale of securities: [Amend]NASDAQ:IONSIonis Pharmaceuticals Inc
12/11/202418:17Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
08/11/202412:52Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:IONSIonis Pharmaceuticals Inc
07/11/202409:05PR Newswire (US)Ionis to present at upcoming investor conferencesNASDAQ:IONSIonis Pharmaceuticals Inc
06/11/202418:06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IONSIonis Pharmaceuticals Inc
06/11/202409:01PR Newswire (US)Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman SyndromeNASDAQ:IONSIonis Pharmaceuticals Inc
06/11/202409:00PR Newswire (US)Ionis reports third quarter 2024 financial resultsNASDAQ:IONSIonis Pharmaceuticals Inc
04/11/202411:44PR Newswire (US)Ionis announces FDA acceptance of New Drug Application for donidalorsen for prophylactic treatment of HAENASDAQ:IONSIonis Pharmaceuticals Inc
23/10/202408:05PR Newswire (US)Ionis to hold third quarter 2024 financial results webcastNASDAQ:IONSIonis Pharmaceuticals Inc
21/10/202403:08PR Newswire (US)WAINZUA (eplontersen) recommended for approval in the EU by CHMP for the treatment of adults with polyneuropathy associated with hereditary transthyretin-mediated amyloidosisNASDAQ:IONSIonis Pharmaceuticals Inc
08/10/202408:30GlobeNewswire Inc.New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMANASDAQ:IONSIonis Pharmaceuticals Inc
03/10/202408:00PR Newswire (US)New positive donidalorsen data to be presented at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific MeetingNASDAQ:IONSIonis Pharmaceuticals Inc
01/10/202419:01Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
01/10/202408:00PR Newswire (US)Zilganersen granted U.S. FDA Fast Track designation for people living with Alexander diseaseNASDAQ:IONSIonis Pharmaceuticals Inc
10/09/202418:19Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:IONSIonis Pharmaceuticals Inc
09/09/202422:10PR Newswire (US)Ionis announces pricing of $500.3 million public offeringNASDAQ:IONSIonis Pharmaceuticals Inc
09/09/202417:20PR Newswire (US)Ionis announces proposed public offering of common stockNASDAQ:IONSIonis Pharmaceuticals Inc
04/09/202422:33Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:IONSIonis Pharmaceuticals Inc
04/09/202408:30GlobeNewswire Inc.Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMANASDAQ:IONSIonis Pharmaceuticals Inc
05/08/202416:35Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:IONSIonis Pharmaceuticals Inc
01/08/202408:00PR Newswire (US)Ionis reports second quarter 2024 financial resultsNASDAQ:IONSIonis Pharmaceuticals Inc
31/07/202410:00PR Newswire (US)Alcyone Therapeutics Announces Continued Enrollment Approval from FDA of the PIERRE Pivotal IDE Clinical Study of the ThecaFlex DRx™ System for Administration of nusinersenNASDAQ:IONSIonis Pharmaceuticals Inc
22/07/202408:00PR Newswire (US)Ionis announces positive detailed results from the HALOS Study of ION582 in people with Angelman syndromeNASDAQ:IONSIonis Pharmaceuticals Inc
19/07/202409:24PR Newswire (US)Ionis to hold second quarter 2024 financial results webcastNASDAQ:IONSIonis Pharmaceuticals Inc
18/07/202408:00PR Newswire (US)Ionis completes enrollment in pivotal trial evaluating zilganersen in people living with Alexander diseaseNASDAQ:IONSIonis Pharmaceuticals Inc
08/07/202408:05PR Newswire (US)Ionis announces webcast to report HALOS study results for ION582 in Angelman syndromeNASDAQ:IONSIonis Pharmaceuticals Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:IONS

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
RCSL4
RECRUSUL PN
BOV
GFSA3
GAFISA ON
BOV
AZEV4
AZEVEDO PN
BOV
IFCM3
Infracommerce Caxaas ON
BOV
FNAM11
Fundo Invest Amazonia Fi...
BOV
PRIO3
PETRORIO ON
BOV
FHER3
FER HERINGER ON
BOV
HOOT4
HOTEIS OTHON PN
BOV
AMOB3
Automob Participacoes ON
BOV
BRAV3
Brava Energia ON
BOV
ALPK3
Allpark Empreendimentos ... ON
BOV
LUPA3
LUPATECH ON
BOV
RCSL3
RECRUSUL ON
BOV
FICT3
Fictor Alimentos ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados